RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
?8-Tetrahydrocannabinol (26), 3-(1?,1?-dimethylbutyl)- (12), 3-(1?,1?-dimethylpentyl)- (13), 3-(1?,1?-dimethylhexyl)- (14) and 3-(1?,1?-dimethylheptyl)-?8-tetrahydrocannabinol (15) have been converted into the corresponding 1-bromo-1-deoxy-?8-tetrahydrocannabinols (25, 8–11). This was accomplished using a protocol developed in our laboratory in which the trifluoromethanesulfonate of a phenol undergoes palladium mediated coupling with pinacolborane. Reaction of this dioxaborolane with aqueous-methanolic copper(II) bromide provides the aryl bromide. The affinities of these bromo cannabinoids for the cannabinoid CB1 and CB2 receptors were determined. All of these compounds showed selectivity for the CB2 receptor and one of them, 1-bromo-1-deoxy-3-(1?,1?-dimethylhexyl)-?8-tetrahydrocannabinol (10), exhibits 52-fold selectivity for this receptor with good (28 nM) affinity.